( January 7, 2025, 2:04 PM EST) -- WASHINGTON, D.C. — The U.S. Patent Trial and Appeal Board (PTAB) did not err when it held that a biopharmaceutical company failed to show that a patent held by another company related to in utero DNA testing is invalid as obvious, a Federal Circuit U.S. Court of Appeals panel held Jan. 6....